UniQure shares jump on trial plans for revamped hemophilia gene therapy – BioPharma Dive
Xconomy |
UniQure shares jump on trial plans for revamped hemophilia gene therapy
BioPharma Dive After meetings with U.S. and European regulators, Dutch biotech uniQure N.V. on Thursday announced plans to move a revamped version of its hemophilia B gene therapy into a pivotal study next year, sending shares in the company sharply higher. The new … For Key Study, UniQure Allowed to Swap Hemophilia Gene Therapies There Could Be 109% Upside In uniQure As Company Advances Gene Therapy Into Clinical Trials In a PhIII showdown with Spark, uniQure switches out its lead gene therapy for hemophilia B |
